By OBBM Network Editorial Staff

The White House

America is finally seeing drug prices tumble to levels unheard of in the modern era – a transformation President Trump called “the biggest day, one of the biggest ever” for medicine and dollars combined.

Most Favored Nation Agreements Deliver Unprecedented Savings

Since launching the Most Favored Nation (MFN) initiative less than a year ago, the Trump administration has negotiated agreements with the world’s 17 top pharmaceutical firms, expanding to 26 companies that together represent 90 percent of the U.S. market. These deals are projected to save Americans billions of dollars, with price reductions ranging from 400% to 600% on many commonly used medications.

“We have slashed the cost of the weight‑loss drug Ozempic by more than $1,800 per year,” the President noted, adding that IVF patients will see “savings on fertility drugs of more than $6,000 per birth.” The discounts are available to all Americans through the new portal TrumpRx.gov.

Reshoring Pharmaceutical Production Boosts Jobs and Security

The administration paired price cuts with a reshoring push, directing companies to invest $19.6 billion in new U.S. manufacturing facilities. In total, agreements amount to $638 billion of pharmaceutical investment, creating jobs and reinforcing national security by ensuring critical drugs are produced domestically.

Howard Lutnick, Secretary of Commerce, emphasized that “reshoring produces national security, we need our drugs made in America, and then that brings jobs and investment in America.” The strategic reserve of active pharmaceutical ingredients, contributed by firms such as UCB, Sun, Pharma, Teva and Estellas, now totals 290 metric tons, further safeguarding supply chains.

Industry Leaders Praise the Collaborative Approach

Key industry figures praised the administration’s willingness to balance low prices with the financial health of drug makers. Dr. Mehmet Oz, Chief Counselor and nominee for Deputy Secretary of Health and Human Services, said, “We are aligning drug pricing with global markets while preserving the United States as the hub for biomedical research.” Astellas announced that its Medicaid prices will match those of developing countries and pledged to donate active drug substance for tacrolimus, a post‑transplant medication.

CEO Chris Klomp, who led the negotiations, highlighted the trust‑based model: “We understood their business models and made it work for them as well as for American patients.” The administration’s directive was clear: achieve the lowest drug prices without bankrupting companies, thereby sustaining innovation.

Historical Context and Future Outlook

The President compared this achievement to the 1962 amendment to the Food, Drug, and Cosmetics Act, which was spurred by the thalidomide tragedy. He argued that, unlike previous administrations, the Trump administration possessed the political will to break the inertia that kept drug prices high.

Looking ahead, the administration plans to extend MFN pricing to additional drugs and continue expanding the strategic reserve. With more companies expected to join the agreements, the promise of lower costs and a robust domestic manufacturing base appears poised to reshape the American health‑care landscape for years to come.

In a nation where prescription costs have long outpaced those of any other developed country, the Trump administration’s bold strategy marks a decisive shift toward affordability, supply‑chain resilience, and renewed confidence in American pharmaceutical leadership.

The full episode of The White House is available on OBBM Network TV.